RVMD Trading Analysis - 10/26/2026 02:12 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge context for Revolution Medicines (RVMD) suggests the following thematic headlines that may relate to its data profile:

• RVMD advances RAS(ON) inhibitor pipeline in mid-stage oncology trials, with upcoming clinical readouts anticipated before year-end 2026.
• Biotech sector sees renewed speculative interest as major index volatility compresses, though high-beta names like RVMD remain susceptible to sharp moves.
• No confirmed earnings date in provided data, but fiscal year end listed as 2025-12-01 with negative EPS indicating pre-profit clinical stage status.
• Institutional ownership near 52.91% reflects moderate sponsor base distinct from broad megacap biotech.
• Headlines imply a catalyst-driven name; options sentiment is bullish while technicals show bearish drift, a divergence observable in embedded data.

Context separation: The above uses external knowledge for framing only. All subsequent sections use strictly embedded RVMD data.

Fundamental Analysis

Based on provided FUNDAMENTALS (source: FinWin fundamentals local, timestamp 2026-10-26):

• Trailing EPS is -8.84; company is non-profitable (clinical stage). Trailing PE, forward PE, PEG, priceToBook, profitMargins, ROE, debtToEquity, freeCashflow, totalRevenue, revenueGrowth all null.
• Market cap 39,477,476,160.00; shares outstanding 214,336,000.00; dividend yield 0.00; no dividend.
• Beta 1.82 (high systematic risk). 52-week high 224.31, low 53.66. Institutional percent 52.91.
• Average volume 2,109,000.00; historical volatility 47.66%.
• Analyst consensus and target price null (no recommendationKey, targetMeanPrice, numberOfAnalystOpinions).
• Fundamentals show negative earnings with no margin/return data; this aligns with bearish technicals (price below SMAs, RSI 37.40) but diverges from bullish options sentiment (74.2% call dollar vol).

Current Market Position

Current price per indicators: 188.10 (calculated 2026-10-26). Minute bars show 2026-10-23 open 187.59, high 189.52, low 183.61, close 188.16; by 2026-10-26 13:45 close 184.19 (low 184.19, high 184.85). Daily history last close 2026-10-23: 188.10. Recent slide from 10-20 close 196.64 to 10-23 188.10 and intraday 10-26 184.19 indicates softening.

Key levels from data: 30-day range high 211.51, low 175.91. Bollinger lower 178.22, upper 212.41. SMA50 201.72, SMA20 195.32, SMA5 190.15. Intraday momentum: last 5 minute bars drift 185.00 to 184.19 on volume uptick (30,827 at 13:45).

Technical Analysis

Price 188.10 below SMA5 190.15, SMA20 195.32, SMA50 201.72: bearish alignment, no golden cross. RSI 37.40 near oversold but not extreme. MACD -3.37 below signal -2.69, histogram -0.67: bearish momentum. Bollinger mid 195.32, price beneath, lower 178.22 acts as support. 30-day range: price at 188.10 is 33% above low 175.91, 11% below high 211.51. ATR 10.48 implies daily swing risk.

True Sentiment Analysis (Delta 40-60 Options)

From RVMD_options_20261026: methodology Delta 40-60 only. Call dollar volume 339,260.00, put 117,690.00, total 456,950.00. Call pct 74.20, put pct 25.80. Sentiment Bullish. Contracts: call 281, put 49; trades call 10, put 6. Filter ratio 1.90% of 846 total.

Conviction: Pure directional call dominance suggests near-term upward expectation. Divergence: technicals bearish (MACD neg, price below SMAs) vs sentiment bullish. Option spread recommendation notes "Divergence detected between technical indicators and options sentiment" with advice to wait for alignment.

Key Price Levels (observational only)